UK To Legalize Three-Parent IVF?

Regulators in England near the approval of a new mitochondrial replacement technique for creating embryos with less risk of developing certain heritable diseases.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Sperm is injected into an oocyte in IVFWIKIMEDIA, EKEMSo called “three-parent” in vitro fertilization (IVF), in which two women and one man contribute DNA to the creation of a human fetus with a reduced risk of developing mitochondrial diseases, came one step closer to becoming a legal procedure last week in the United Kingdom. The UK Department of Health announced on Thursday (February 27) that it was opening a three-month public comment period on draft legislation that would legalize oocyte modification, an IVF method that involves transferring nuclear DNA from an egg cell of a woman with mitochondrial defects into the egg cell of an IVF donor egg with normal mitochondrial DNA before using donor sperm to fertilize the egg. “This is very good news for patients with mitochondrial DNA disease and an important step in the prevention of transmission of serious mitochondrial disease,” Newcastle University’s Doug Turnbull, who conducts research on the procedure, told The Guardian.

The announcement follows the US Food and Drug Administration’s decision last week to gather public comment on the IVF technique’s future in the United States. But approval of the procedure could happen sooner in the U.K. After the public consultation ends there on May 21, the UK government will decide whether to put the legislation before parliament for approval. Jeremy Farrar, director of the Wellcome Trust, told The Guardian that he hoped the government would act quickly. "Once further public consultation on the detail of these regulations is complete, we urge the government to move swiftly so that parliament can debate the regulations at the earliest opportunity and families affected by these devastating disorders can begin to benefit," he said.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours